Company news
Satellos Bioscience Inc news in 2023
Satellos Bioscience Inc's news releases, calls and decks from 2023, newest first.
Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
September 20, 2023
Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services
September 7, 2023
Satellos Expands Leadership Team with New CFO Appointment
September 5, 2023
Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights
August 29, 2023
TSX Venture Exchange, Satellos Bioscience Inc., View From The C-Suite
August 21, 2023
Satellos Bioscience Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy
August 2, 2023
Satellos Bioscience Announces Results from Its Annual General Meeting of Shareholders and Adoption of Amendments to Stock Option Plan
June 30, 2023
Satellos Bioscience Announces Appointment of Chief Medical Officer
June 7, 2023
Satellos Bioscience Announces Grant of Stock Options
June 1, 2023
Satellos Bioscience Announces 2023 Q1 Financial Results and Operational Highlights
May 30, 2023
Satellos Bioscience Closes $55M Financing to Support Development of its Lead Drug Candidate for Duchenne Muscular Dystrophy
May 17, 2023
Satellos Bioscience Inc. Announces Filing of Final Short Form Prospectus for Proposed Offering of Common Shares
May 10, 2023
Satellos Bioscience Inc. Announces Pricing of Public Offering
April 19, 2023
Satellos Bioscience Inc. Announces Public Offering of Common Shares
April 18, 2023
Satellos Bioscience Announces 2022 Year End Financial Results and Operational Highlights
March 30, 2023
Satellos Bioscience Announces Closing of Previously Announced Non-Brokered Offering of $2.385 Million of Unsecured Non-Convertible Debentures
March 29, 2023
Satellos Bioscience Announces Upsize of Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures to up to $2.385 Million
March 22, 2023
Satellos Bioscience to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit
March 17, 2023
Satellos Bioscience Announces Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures of up to $2.25 Million
March 15, 2023
Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 As a Potential Treatment for Duchenne Muscular Dystrophy
March 10, 2023
Satellos Bioscience Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model
February 6, 2023
Satellos Bioscience Announces Development Candidate
January 3, 2023